
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBAChairman of the Board and Chief Executive Officer, AbbVie

Dr. Dereck Mush, MD, MBAMentions AbbVie

Dr. Dereck Mush, MD, MBAMentions AbbVie

Dr. Dereck Mush, MD, MBAMentions AbbVie
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: